骨髓间充质干细胞在肝硬化治疗中的研究进展

Bone marrow mesenchymal stem cells for treatment of liver cirrhosis

肝病是全球范围内的多发病.中国是肝炎、肝硬化疾病高发国家,并有逐年增加的趋势.随着慢性肝脏疾病病情进展,可诱发上消化道出血、肝癌等恶性疾患,对患者健康及生存质量造成严重威胁.故在病程转入肝硬化前,选择一种有效的治疗方法,可逆转病情、改善预后、降低病死率.近年来探索了多种治疗肝硬化的新方法,并取得了显著的效果,其中骨髓间充质干细胞(bone marrow mesenchymal stem cells)是目前研究最热门的种子细胞.他既能在体内微环境作用下分化为肝细胞,又能在受损肝组织内分泌细胞因子减轻炎症反应、抑制细胞凋亡、改善肝功能等,有望成为治疗肝硬化、肝衰竭的新策略.

Liver disease is a frequently occurring disease worldwide.In China,the incidence of hepatitis and liver cirrhosis is high,and has increased year by year.The progression of chronic liver disease can lead to upper gastrointestinal bleeding,liver cancer and other malignant diseases,posing a serious threat to the health and quality of life of patients.Before progression to liver cirrhosis,choosing an effective treatment method can reverse the disease,improve the prognosis and reduce mortality.Bone marrow mesenchymal stem cells（BMSCs） are the most popular seed cells in the development of new methods for treating cirrhosis.They can not only differentiate into hepatocytes in vivo,but also reduce the inflammatory response,inhibit cell apoptosis,improve liver function and so on.BMSCs are expected to be a new strategy for the treatment of liver cirrhosis and liver failure.